References
- André N, Carré M, Brasseur G, Pourroy B, Kovacic H, Briand C, Braguer D. (2002). Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett, 532, 256–260.
- Bhalla KN. (2003). Microtubule-targeted anticancer agents and apoptosis. Oncogene, 22, 9075–9086.
- Boddapati SV, D’Souza GG, Erdogan S, Torchilin VP, Weissig V. (2008). Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett, 8, 2559–2563.
- Boddapati SV, Tongcharoensirikul P, Hanson RN, D’Souza GG, Torchilin VP, Weissig V. (2005). Mitochondriotropic liposomes. J Liposome Res, 15, 49–58.
- Borutaite V. (2010). Mitochondria as decision-makers in cell death. Environ Mol Mutagen, 51, 406–416.
- D’Souza GG, Rammohan R, Cheng SM, Torchilin VP, Weissig V. (2003). DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control Release, 92, 189–197.
- Ferlini C, Cicchillitti L, Raspaglio G, Bartollino S, Cimitan S, Bertucci C, Mozzetti S, Gallo D, Persico M, Fattorusso C, Campiani G, Scambia G. (2009). Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res, 69, 6906–6914.
- Holt IJ, Harding AE, Morgan-Hughes JA. (1988). Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature, 331, 717–719.
- Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA. (1990). A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet, 46, 428–433.
- Horobin RW, Trapp S, Weissig V. (2007). Mitochondriotropics: a review of their mode of action, and their applications for drug and DNA delivery to mammalian mitochondria. J Control Release, 121, 125–136.
- Kidd JF, Pilkington MF, Schell MJ, Fogarty KE, Skepper JN, Taylor CW, Thorn P. (2002). Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem, 277, 6504–6510.
- King A, Selak MA, Gottlieb E. (2006). Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene, 25, 4675–4682.
- Norberg E, Orrenius S, Zhivotovsky B. (2010). Mitochondrial regulation of cell death: processing of apoptosis-inducing factor (AIF). Biochem Biophys Res Commun, 396, 95–100.
- Patel NR, Hatziantoniou S, Georgopoulos A, Demetzos C, Torchilin VP, Weissig V, D’Souza GG. (2010). Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol. J Liposome Res, 20, 244–249.
- Schiff PB, Fant J, Horwitz SB. (1979). Promotion of microtubule assembly in vitro by Taxol. Nature, 277, 665–667.
- Schon EA, DiMauro S. (2003). Medicinal and genetic approaches to the treatment of mitochondrial disease. Curr Med Chem, 10, 2523–2533.
- Shimizu S, Eguchi Y, Kamiike W, Funahashi Y, Mignon A, Lacronique V, Matsuda H, Tsujimoto Y. (1998). Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux. Proc Natl Acad Sci USA, 95, 1455–1459.
- Torchilin VP. (2006). Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng, 8, 343–375.
- Torchilin VP, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL, Rammohan R, Samokhin GP, Whiteman KR. (2001). p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta, 1511, 397–411.
- Wallace DC. (1999). Mitochondrial diseases in man and mouse. Science, 283, 1482–1488.
- Yamada Y, Akita H, Kogure K, Kamiya H, Harashima H. (2007). Mitochondrial drug delivery and mitochondrial disease therapy—an approach to liposome-based delivery targeted to mitochondria. Mitochondrion, 7, 63–71.